论文部分内容阅读
目的探讨中药健脾理气合剂阻抑ＨＢＶ与ＡＦＢ１协同致肝癌作用机制．方法用ＰＣＲ技术结合Ｓｏｕｔｈｅｒｎ杂交方法，筛选出５０只Ｇ３代ＨＢＶ转基因小鼠，分成两组：转基因治疗组与转基因对照组，另选择２５只同龄非转基因小鼠作正常对照组．小鼠１０ｗｋ时，予治疗组小鼠，按２５ｇ／（ｋｇ·ｄ）灌服健脾理气合剂，两对照组小鼠灌服等体积生理盐水共１５ｄ．ｄ１６，按１ｍｇ／ｋｇｉｐＡＦＢ１（０ｈ相小鼠不注射）．用ＲＩＡ法测定暴露ＡＦＢ１后７个不同时相小鼠肝脏ＡＦＢ１ＤＮＡ加成物的含量，并检测小鼠肝脏与ＡＦＢ１代谢相关的两相酶系活性．结果健脾理气合剂能使ＨＢＶ转基因小鼠暴露ＡＦＢ１后１ｈ（５５９±４２）及２４ｈ（２４９±２０）相升高的肝脏ＡＦＢ１ＤＮＡ加成物水平（ｎｍｏｌ／ｇ）降至近正常水平（４２０±３０，１１１±１３；Ｐ＜００１），并能提高转基因小鼠肝脏Ｐ４５０（μｍｏｌ／ｇ，０８７±０２５→１２９±０２６，Ｐ＜００５），谷胱甘肽（ｎｍｏｌ／ｇ，５２８±０９５→７６７±０７６，Ｐ＜００１）含量及激活ＧＳＴ活性（ｍｍｏｌ·Ｌ－１·ｍｉｎ－１·ｇ－１，３７１±０９５→５５８±０７５，Ｐ＜００１）?
2. Objective To explore the mechanism of Jianpi Liqi Mixture on inhibiting the cooperation between HBV and AFB1 in liver cancer induced by hepatoma. METHODS: Fifty G3 generation HBV transgenic mice were screened by PCR and Southern blotting methods and divided into two groups: transgene treatment group and transgenic control group. Another 25 non-transgenic mice of the same age were selected as normal control group. When the mice were treated for 10 weeks, the mice in the treatment group were given Jianpi Liqi Mixture at 25g/(kg·d), and the mice in the two control groups were given an equal volume of normal saline for 15 days. D16, according to 1mg/kgipAFB1 (0h phase mice are not injected). The content of AFB1 DNA adducts in livers of mice at 7 different phases after exposure to AFB1 was determined by RIA method, and the two-phase enzyme activities related to AFB1 metabolism in livers of mice were detected. Results Jianpi Liqi Mixture could reduce the level of liver AFB1 DNA (nmol/g) in HBV transgenic mice at 1h (559±42) and 24h (249±20) after exposure to AFB1 to near normal level (420 ±30,111±13; P<001), and can increase the liver P450 in transgenic mice (μmol/g, 087±025→129±026, P<005), Glutathione (nmol/g, 528±095→767±076, P<001) content and activated GST activity (mmol·L-1·min-1·g-1) , 371±095→558±075, P<001)?